Trials / Completed
CompletedNCT00394121
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
Long-term Open-label Safety Study With SkyePharma FlutiForm HFA pMDI (100/10 µg and 250/10 µg) in Adult and Adolescent Patients With Asthma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- SkyePharma AG · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety of the fixed combination asthma drug FlutiForm HFA MDI (containing fluticasone propionate and formoterol fumarate) in adult and adolescent patients with mild to moderate-severe asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluticasone propionate/formoterol fumarate |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2006-10-31
- Last updated
- 2010-08-27
Locations
28 sites across 5 countries: Germany, Hungary, Poland, Romania, United Kingdom
Source: ClinicalTrials.gov record NCT00394121. Inclusion in this directory is not an endorsement.